Media
View our latest materials to follow our progress in tackling respiratory diseases.
Latest Videos
View all videos
Filters
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)
Verona Pharma Announces August 2021 Virtual Investor Conference Participation
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company). Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties. Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China.
Verona Pharma
Investor Information
© Verona Pharma plc 2021. All rights reserved